Therapy for Triple Receptor-Negative Breast Cancer with Residual Invasive Cancer or Positive Lymph Nodes

Status: open

A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer with >/= 1 CM Residual Invasive Cancer or Positive Lymph Nodes (ypN+) after Neoadjuvant Chemothera

Treatment for Breast Cancer

Contact Us Or call (251) 445-9834

Description

This randomized phase III trial studies how well pembrolizumab works in treating triple-negative breast cancer. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread.

Sponsors

This trial is sponsored by SWOG.
This link will open in a new tab or window.